Clearing The Cobwebs
Roche-reMYND partner on disease-modifying compounds for Alzheimer's, Parkinson's
Roche is placing a bet that reMYND N.V.'s approach to clearing misfolded proteins from the CNS could yield disease-modifying treatments for Alzheimer's disease and Parkinson's disease. Proving it will require the partners to develop a toolkit that includes biomarkers and diagnostics that can identify presymptomatic patients, as well as new clinical endpoints that measure disease modification.
The partners will develop two of reMYND's preclinical programs for AD and PD. Both are focused on small molecules that stimulate degradation of a misfolded protein that would otherwise lead to neurotoxicity.